To include your compound in the COVID-19 Resource Center, submit it here.

Xarelto lowers CV risk, ups major bleeds in Phase III for artery disease

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported full data from the Phase III COMPASS trial showing that twice-daily 2.5 mg oral Xarelto rivaroxaban (BAY 59-7939) plus once-daily 100 mg aspirin significantly reduced the proportion of coronary and/or peripheral artery disease (CAD/PAD) patients with cardiovascular

Read the full 502 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers